Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

Multiple Sclerosis Clinical Trial

— MODIF-MS  

Official title:

A Phase 2 Trial Assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06330077
• Other study ID #: APHP200027
• Secondary ID: 2021-003584-99
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 2024
• Est. completion date: June 2027

Study information

• Verified date: September 2023
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Bruno STANKOFF, MD
• Phone: 0171970659
• Email: bruno.stankoff[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multiple sclerosis (MS) is the most frequently acquired demyelinating disease and the first cause of non-traumatic chronic disability in young adults. Major progress has been achieved in the treatment of MS through the development of therapies targeting the adaptative immune system, which drastically reduce the relapse rate, with various efficiency and safety profiles (Ontaneda, 2015). However, these drugs generally fail to prevent disability worsening along the disease course, and we are now assisting to a shift in therapeutic objectives from the development of new immune drugs towards the identification of therapeutic strategies that could prevent neurodegeneration by promoting myelin regeneration (Stangel, 2017; Stankoff, 2016), in order to prevent neurological disability in MS (Irvine and Blakemore, 2008; Patrikios, 2006; Duncan I, 2017, Bodini, 2016).

Among the first candidate compounds developed to promote remyelination was the anti Lingo1 antibody, which enhance remyelination (Mi, 2009). Medium and large throughput screening of drug libraries subsequently identified several chemical classes of compounds with strong promyelinating properties, such as the antifongic drug miconazole (Najm, 2015) or the muscarinic antagonist clemastine (Wei, 2014). A recent innovative trial has investigated the effect of clemastine, compared to placebo, in a small sample of subjects (25 patients per group) and showed that clemastine could significantly improve the optic nerve conduction speed which reflecting myelin integrity and functionality (Green, 2017).

Our preclinical research has allowed us to identify ifenprodil as a powerful drug to promote myelin repair in vitro and in vivo across species. In parallel our team recently pioneered and optimized a PET imaging approach for quantifying remyelination in the whole brain, that allowed to enhance the sensitivity to detect the myelin repair process, and showed that patients are characterized by heterogeneous profiles of spontaneous remyelination profiles that are closely linked to disability accrual (Bodini, 2016).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: June 2027
• Est. primary completion date: March 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

-

Patients:

1. Signed informed consent form at pre-inclusion visit

2. Age between 18 years and 55 years, inclusive, at time of pre-inclusion visit.

3. Patient with a RR form of MS according McDonald criteria 2017 at pre-inclusion visit

4. Able to comply with the study protocol and to understand the purpose and risks of the study, in the investigator's judgment

5. Social security registration (AME excluded) at time of pre-inclusion visit

6. At least one eye with a P100 latency > 118ms on visual evoked potential at baseline (defining the qualifying eye) at time of pre-inclusion visit

7. Retinal nerve fibre layer thickness on spectral-domain optical coherence tomography [OCT] > 70 µm in the VEP qualifying eye (to increase the likelihood that the number of surviving axons is sufficient to provide the substrate for remyelination to occur) at time of pre-inclusion visit

8. Patient under disease modifying therapy (first or second line approved immune active therapy) or patient without any DMT at time of pre-inclusion visit

9. EDSS score = 6 at time of pre-inclusion visit

10. For women of childbearing potential : Efficient contraception include oral contraception, intrauterine devices hormonal device, intrauterine hormone-releasing system, sterilization method and other forms of contraception with failure rate <1%)

• Healthy Volunteers

1. Signed informed consent form 2. Age between 18 years and 55 years, inclusive 3. All female subjects of childbearing potential must practice effective contraception include oral contraception, intrauterine devices hormonal device, intrauterine hormone-releasing system, sterilization method and other forms of contraception with failure rate <1%) 4. Able to comply with the study protocol, in the investigator's judgment 5. Social security registration (AME excluded)

Exclusion Criteria:

Patients

1. Patient with an acute NORB in the last 6 months prior to pre-inclusion visit

2. Patient with a clinical relapse other than NORB in the last 6 months prior to pre-inclusion visit

3. Patients having received methylprednisolone infusion in the last 4 weeks prior to pre-inclusion visit

4. Contraindications to investigational medicinal products (ifenprodil/placebo) and to auxiliary medicinal products (gadolinium, [18F]-florbetaben)

5. Inability to complete an MRI (contraindications for MRI include but are not restricted to weight = 140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, contraindication to gadoteric acid etc.).

6. PET imaging performed in the past 12 months as part of clinical research

7. History or incidental discovery of significant cardiac conduction block

8. Orthostatic hypotension Syndrome define as a drop of > 20 mmHg in systolic, and/or > 10 mmHg in diastolic between lying down and immediate standing

9. Known long QT syndrome or long QT syndrome (the limit is defined at 450 ms on corrected QT) highlighted during the pre-inclusion visit

10. Any uncontrolled general (cancer, infectious, hematologic, hepatic, immunologic, endocrinologic, neurologic, dermatologic, psychiatric, allergic, renal, or cardiovascular) disease.

11. Creatinine clearance < 60 ml/min at pre-inclusion visit

12. ASAT, ALAT of alkaline phosphatase > 3-fold the upper limit normal at pre-inclusion visit

13. Know Galactosemia, glucose malabsorption or lactase deficiency

14. Known of lack of peripheral venous access or lack of peripheral venous access highlighted during the pre-inclusion visit

15. Thrombocytopenia with platelets < 100 000/mm3

16. Pregnancy and/or lactating women

17. Legal protection (curatorship or tutorship)

18. Deprive of freedom or under security measure

19. Participation in another interventional trial evaluating a health product or any randomized trial or being in the exclusion period at the end of a previous study

20. Refusal to be informed in case of clinically significant incidental discovery after MRI

21. Patient treated for hypertension with the following drugs blocking the alpha-adrenergic system either in periphery (prazosine, urapidil, moxisylyte, labetalol) or centrally (clonidine, monoxidine, methyldopa)

Healthy Volunteers

1. Inability to complete an MRI (contraindications for MRI include but are not restricted to weight = 140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc).

2. Impossibility to complete a PET scan: pregnancy, nuclear medicine irradiation for clinical research in the year preceding baseline visit.

3. Contraindication to auxiliary medicinal products ([18F]-florbetaben)

4. Known presence of any neurological disorders

5. Pregnancy and/or lactation

6. Lack of peripheral venous access

7. Terminal renal insufficiency (Creatinin clearance < 60 ml/min)

8. Legal protection (curatorship or tutorship)

9. Deprive of freedom or under security measure

10. Participation in another interventional trial evaluating a health product or any randomized trial or being in the exclusion period at the end of a previous study

11. Refusal to be informed in case of clinically significant incidental discovery after MRI

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Sclerosis

Intervention

Drug:
• Ifenprodil
Treatment administration
• Placebo
Treatment administration

Locations

Country	Name	City	State
France	Hôpital Neurologique Pierre WERTHEIMER - HCL	Bron
France	Groupe Hospitalier Pitié Salpêtrière - APHP	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in P100 latency according to visual evoked potential.	Assess the efficacy of ifenprodil on the remyelination of the optic nerve measured as the improvement of P100 latency, assessed using full field visual evoked potentials.	Between months 6 and months 12
Secondary	Proportion of voxels within white matter lesions classified as remyelinating	Change in remyelination potential measured by PET-MR Between M6 (end of run-in, calculation of pre-treatment remyelination potential, randomization) and M12 (end of follow-up, calculation of post-treatment remyelination potential) in each group.	Between 6 months and 12 months
Secondary	Proportion of remyelinating voxels extracted in cortical regions from magnetization transfer imaging (MTR) acquisitions	Change in the proportion of remyelinating voxels extracted in cortical regions from MTR acquisitions (as cortical myelin in not assessed by PET) between M6 and M12 in each group	Between 6 months and 12 months
Secondary	Change in amplitude of P100 on to visual evoked potential	o determine whether the treatment by ifenprodil could influence axonal damage in the visual pathway assessed by the amplitude of P100	Between 6 months and 12 months
Secondary	Change in retinal nerve fibre layer (RNFL) and ganglion cell complex (GCC) thickness on OCT	To determine whether the treatment by ifenprodil could influence neurodegeneration measured by optical coherence tomography (OCT) parameters in each group	Between 6 months and 12 months
Secondary	Change in blood concentration of NfL fragments	To determine whether the treatment by ifenprodil could influence axonal damage assessed by the blood concentration of neurofilament light chain (NfL) in each group	From Pre-inclusion visit to 6 months and from 6 months to 9 months and 6 months to 12 months
Secondary	Change in the brain atrophy rate	To determine whether the treatment by ifenprodil could influence white matter lesions load or brain atrophy rate in each group	From baseline to 6 months and 6 months to 12 months
Secondary	The correlation between the change in the proportion of remyelinating voxels extracted in white matter lesions from [18F]florbetaben PET acquisitions	To determine whether the efficacy of ifenprodil is influenced by endogenous remyelination profiles assessed in the run-in period, and to describe the profile of optimal responders	Between 6 months and 12 months and the pre-treatment individual remyelination profiles as determined during the Run-in period
Secondary	The comparison of the proportion of remyelinating voxels extracted in white matter lesions from [18F]florbetaben PET acquisitions	To assess whether the disease modifying therapies received during the study influence the remyelination level and/or the ifenprodil effect on remyelination	Between 6 months and 12 months
Secondary	Incidence of adverse drug reactions		Between inclusion and 12 months